These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2328 related articles for article (PubMed ID: 23278193)

  • 21. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-phase 18F-FDG PET/CT imaging in the characterization of pancreatic lesions: does it offer prognostic information?
    Santhosh S; Mittal BR; Bhasin D; Rana SS; Bhattacharya A; Srinivasan R; Nada R; Gupta R
    Nucl Med Commun; 2014 Oct; 35(10):1018-25. PubMed ID: 25023999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing the performance of visual estimation and standard uptake value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography for detecting malignancy in pancreatic tumors other than invasive ductal carcinoma.
    Otomi Y; Otsuka H; Terazawa K; Nose H; Kubo M; Matsuzaki K; Ikushima H; Bando Y; Harada M
    J Med Invest; 2014; 61(1-2):171-9. PubMed ID: 24705763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic signatures of malignant and non-malignant mass-forming lesions in the periampulla and pancreas in FDG PET/CT scan: an atlas with pathologic correlation.
    Santhosh S; Mittal BR; Rana SS; Srinivasan R; Bhattacharya A; Das A; Bhasin D
    Abdom Imaging; 2015 Jun; 40(5):1285-315. PubMed ID: 25296997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
    Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
    Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidental colonic focal FDG uptake on PET/CT: can the maximum standardized uptake value (SUVmax) guide us in the timing of colonoscopy?
    van Hoeij FB; Keijsers RG; Loffeld BC; Dun G; Stadhouders PH; Weusten BL
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):66-71. PubMed ID: 25139518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (18)F-FDG-PET/CT findings in pancreatic metastasis.
    Hu S; Zhang J; Zuo C; Cheng C; Liu Q; Sun G
    Radiol Med; 2015 Oct; 120(10):887-98. PubMed ID: 25795439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.
    Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
    Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidental focal colorectal ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography.
    Cho SH; Kim SW; Kim WC; Park JM; Yoo IeR; Kim SH; Oh ST
    World J Gastroenterol; 2013 Jun; 19(22):3453-8. PubMed ID: 23801838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas.
    Sperti C; Pasquali C; Chierichetti F; Liessi G; Ferlin G; Pedrazzoli S
    Ann Surg; 2001 Nov; 234(5):675-80. PubMed ID: 11685032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
    Voth M; Opfermann T; Gottschild D
    Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis.
    Hu S; Zhang J; Cheng C; Liu Q; Sun G; Zuo C
    Abdom Imaging; 2014 Dec; 39(6):1221-7. PubMed ID: 24913670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
    Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 117.